These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37191097)

  • 1. Real-world outcomes in metastatic HR+/HER2-, HER2+ and triple negative breast cancer after start of first-line therapy.
    W DeClue R; Fisher MD; Gooden K; Walker MS; Le TK
    Future Oncol; 2023 Apr; 19(13):909-923. PubMed ID: 37191097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.
    Masuda H; Brewer TM; Liu DD; Iwamoto T; Shen Y; Hsu L; Willey JS; Gonzalez-Angulo AM; Chavez-MacGregor M; Fouad TM; Woodward WA; Reuben JM; Valero V; Alvarez RH; Hortobagyi GN; Ueno NT
    Ann Oncol; 2014 Feb; 25(2):384-91. PubMed ID: 24351399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Outcomes, Treatment Patterns, and Health Resource Utilization Among Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutation: A Real-World Retrospective Study.
    Quek RGW; Mardekian J
    Adv Ther; 2019 Mar; 36(3):708-720. PubMed ID: 30656571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer-results from an international, multicenter analysis coordinated by the AGMT Study Group.
    Gampenrieder SP; Dezentjé V; Lambertini M; de Nonneville A; Marhold M; Le Du F; Cortés Salgado A; Alpuim Costa D; Vaz Batista M; Chic Ruché N; Tinchon C; Petzer A; Blondeaux E; Del Mastro L; Targato G; Bertucci F; Gonçalves A; Viret F; Bartsch R; Mannsbart C; Deleuze A; Robert L; Saavedra Serrano C; Gion Cortés M; Sampaio-Alves M; Vitorino M; Pecen L; Singer C; Harbeck N; Rinnerthaler G; Greil R;
    ESMO Open; 2023 Feb; 8(1):100747. PubMed ID: 36563519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world clinical outcomes of patients with BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: a CancerLinQ® study.
    Miller RS; Mokiou S; Taylor A; Sun P; Baria K
    Breast Cancer Res Treat; 2022 May; 193(1):83-94. PubMed ID: 35194731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice.
    Brufsky A; Liu X; Li B; McRoy L; Layman RM
    Target Oncol; 2021 Sep; 16(5):601-611. PubMed ID: 34338965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term treatment patterns and survival in metastatic breast cancer by intrinsic subtypes - an observational cohort study in Sweden.
    Lindman H; Wiklund F; Andersen KK
    BMC Cancer; 2022 Sep; 22(1):1006. PubMed ID: 36138404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer.
    Dent RA; Cescon DW; Bachelot T; Jung KH; Shao ZM; Saji S; Traina TA; Vukovic P; Mapiye D; Maxwell MJ; Schmid P; Cortés J
    Future Oncol; 2023 Nov; 19(35):2349-2359. PubMed ID: 37526149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant treatment and survival outcomes by pathologic complete response in HER2-negative early breast cancers.
    Crosbie A; Le TK; Zhang Y; Das R; Ades F; Davis C; Gogate A
    Future Oncol; 2023 Jan; 19(3):229-244. PubMed ID: 36974619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Clinical Outcomes in Biological Subgroups of Breast Cancer in the Hospital District of Southwest Finland.
    Teerenhovi H; Tuominen S; Nurmi-Rantala S; Hemmilä P; Ellonen A
    Oncologist; 2021 Aug; 26(8):e1372-e1380. PubMed ID: 33955109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of chemotherapy relative dose intensity on cause-specific and overall survival for stage I-III breast cancer: ER+/PR+, HER2- vs. triple-negative.
    Zhang L; Yu Q; Wu XC; Hsieh MC; Loch M; Chen VW; Fontham E; Ferguson T
    Breast Cancer Res Treat; 2018 May; 169(1):175-187. PubMed ID: 29368311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort.
    Galvin A; Courtinard C; Bouteiller F; Gourgou S; Dalenc F; Jacot W; Arnedos M; Bailleux C; Dieras V; Petit T; Emile G; Dubray-Longeras P; Frenel JS; Bachelot T; Mailliez A; Brain E; Desmoulins I; Massard V; Patsouris A; Goncalves A; Grinda T; Delaloge S; Bellera C
    Eur J Cancer; 2024 Jan; 196():113422. PubMed ID: 37977105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016.
    Deluche E; Antoine A; Bachelot T; Lardy-Cleaud A; Dieras V; Brain E; Debled M; Jacot W; Mouret-Reynier MA; Goncalves A; Dalenc F; Patsouris A; Ferrero JM; Levy C; Lorgis V; Vanlemmens L; Lefeuvre-Plesse C; Mathoulin-Pelissier S; Petit T; Uwer L; Jouannaud C; Leheurteur M; Lacroix-Triki M; Courtinard C; Perol D; Robain M; Delaloge S
    Eur J Cancer; 2020 Apr; 129():60-70. PubMed ID: 32135312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world treatment patterns and effectiveness outcomes in patients with early-stage triple-negative breast cancer.
    Haiderali A; Rhodes WC; Gautam S; Huang M; Sieluk J; Skinner KE; Schwartzberg LS
    Future Oncol; 2021 Oct; 17(29):3819-3831. PubMed ID: 34227400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy.
    Alabdulkareem H; Pinchinat T; Khan S; Landers A; Christos P; Simmons R; Moo TA
    Breast J; 2018 Mar; 24(2):148-153. PubMed ID: 28707744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and economic outcomes by first-line treatment among women with HR+/HER2- metastatic breast cancer in a large US health plan database.
    Burton T; Byfield SD; Smith GL; Zanotti G; Bell TJ; Perkins JJ; Horblyuk R; Teitelbaum A
    Curr Med Res Opin; 2016 Aug; 32(8):1417-23. PubMed ID: 27074160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical, Pathological Complete Response, and Prognosis Characteristics of HER2-Low Breast Cancer in the Neoadjuvant Chemotherapy Setting: A Retrospective Analysis.
    Shao Y; Yu Y; Luo Z; Guan H; Zhu F; He Y; Chen Q; Liu C; Nie B; Liu H
    Ann Surg Oncol; 2022 Dec; 29(13):8026-8034. PubMed ID: 35933542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical activity of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer: A phase IB/II study (KCSG BR18-16).
    Kim SH; Im SA; Suh KJ; Lee KH; Kim MH; Sohn J; Park YH; Kim JY; Jeong JH; Lee KE; Choi IS; Park KH; Kim HJ; Cho EK; Park SY; Kim M; Kim JH
    Eur J Cancer; 2023 Dec; 195():113386. PubMed ID: 37890351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort.
    Grinda T; Antoine A; Jacot W; Blaye C; Cottu PH; Diéras V; Dalenc F; Gonçalves A; Debled M; Patsouris A; Mouret-Reynier MA; Mailliez A; Clatot F; Levy C; Ferrero JM; Desmoulins I; Uwer L; Petit T; Jouannaud C; Lacroix-Triki M; Deluche E; Robain M; Courtinard C; Bachelot T; Brain E; Pérol D; Delaloge S
    ESMO Open; 2021 Jun; 6(3):100114. PubMed ID: 33895695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of SIRT1, SIRT3 and SIRT6 Genes for Predicting Survival in Triple-Negative and Hormone Receptor-Positive Subtypes of Breast Cancer.
    Uzelac B; Krivokuca A; Brankovic-Magic M; Magic Z; Susnjar S; Milovanovic Z; Supic G
    Pathol Oncol Res; 2020 Oct; 26(4):2723-2731. PubMed ID: 32681437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.